New weight-loss drug combines naltrexone and bupropion

However, the withdrawal rates from earlier trials was as high as 50%

A new combination weight loss pill has been approved by the TGA for use nearly 15 years after it was developed by an Australian physiologist.

scales

The medication (Contrave, by iNova) contains a combination of the opioid antagonist naltrexone and the anti-cravings drug bupropion.

It is indicated for patients with obesity (a BMI over 30) or in patients who have a BMI over 27 plus one or more weight-related comorbidities, such as type 2 diabetes.

In one US trial, 44% of participants who were overweight or obese with type 2 diabetes achieved more than 5% total

Latest

Trending